Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

News Daily News

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

December 15, 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

News Conference News NY Valves 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

Michael O'Riordan

June 12, 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

April 15, 2024

More ARNI Insights Fortify Role in ‘Below Normal’ LVEF: PARAGLIDE-HF

News Conference News ESC Heart Failure 2023

More ARNI Insights Fortify Role in ‘Below Normal’ LVEF: PARAGLIDE-HF

May 22, 2023

May 2023 News Roundup

News Opinion CV Team Dispatch

May 2023 News Roundup

May 01, 2023

Poor Outcomes in HF Patients With Moderate Aortic Stenosis: Observational Data

News Daily News

Poor Outcomes in HF Patients With Moderate Aortic Stenosis: Observational Data

Michael O'Riordan

March 29, 2023

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

News Daily News

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

June 03, 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

May 15, 2021

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

News Daily News

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

Michael O'Riordan

April 15, 2021

Higher Risk of HF After ACS for Women Previously on Beta-blockers

News Daily News

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Michael O'Riordan

July 16, 2020

TCTMD’s Top 10 Most Popular Stories for December 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2018

January 01, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.